0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Multiple Sclerosis Therapies Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-18O14187
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Multiple Sclerosis Therapies Market Research Report 2023
BUY CHAPTERS

Global Multiple Sclerosis Therapies Market Research Report 2025

Code: QYRE-Auto-18O14187
Report
June 2025
Pages:74
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Multiple Sclerosis Therapies Market Size

The global market for Multiple Sclerosis Therapies was valued at US$ 23820 million in the year 2024 and is projected to reach a revised size of US$ 30120 million by 2031, growing at a CAGR of 3.5% during the forecast period.

Multiple Sclerosis Therapies Market

Multiple Sclerosis Therapies Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Multiple Sclerosis Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Sclerosis Therapies.
The Multiple Sclerosis Therapies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Multiple Sclerosis Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Sclerosis Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Multiple Sclerosis Therapies Market Report

Report Metric Details
Report Name Multiple Sclerosis Therapies Market
Accounted market size in year US$ 23820 million
Forecasted market size in 2031 US$ 30120 million
CAGR 3.5%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Acute Attack Treatment
  • Disease Remission Treatment
Segment by Application
  • Hospital
  • Clinic
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Bayer, Biogen, Bristol Myers Squibb, Roche, GSK, Merck Group, Novartis, Teva Pharmaceutical Industries, Sanofi
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Multiple Sclerosis Therapies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Multiple Sclerosis Therapies Market growing?

Ans: The Multiple Sclerosis Therapies Market witnessing a CAGR of 3.5% during the forecast period 2025-2031.

What is the Multiple Sclerosis Therapies Market size in 2031?

Ans: The Multiple Sclerosis Therapies Market size in 2031 will be US$ 30120 million.

Who are the main players in the Multiple Sclerosis Therapies Market report?

Ans: The main players in the Multiple Sclerosis Therapies Market are Bayer, Biogen, Bristol Myers Squibb, Roche, GSK, Merck Group, Novartis, Teva Pharmaceutical Industries, Sanofi

What are the Application segmentation covered in the Multiple Sclerosis Therapies Market report?

Ans: The Applications covered in the Multiple Sclerosis Therapies Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Multiple Sclerosis Therapies Market report?

Ans: The Types covered in the Multiple Sclerosis Therapies Market report are Acute Attack Treatment, Disease Remission Treatment

Recommended Reports

Neurotherapeutics

Autoimmune & Therapy

CNS & Mental Health

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Multiple Sclerosis Therapies Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Acute Attack Treatment
1.2.3 Disease Remission Treatment
1.3 Market by Application
1.3.1 Global Multiple Sclerosis Therapies Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Multiple Sclerosis Therapies Market Perspective (2020-2031)
2.2 Global Multiple Sclerosis Therapies Growth Trends by Region
2.2.1 Global Multiple Sclerosis Therapies Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Multiple Sclerosis Therapies Historic Market Size by Region (2020-2025)
2.2.3 Multiple Sclerosis Therapies Forecasted Market Size by Region (2026-2031)
2.3 Multiple Sclerosis Therapies Market Dynamics
2.3.1 Multiple Sclerosis Therapies Industry Trends
2.3.2 Multiple Sclerosis Therapies Market Drivers
2.3.3 Multiple Sclerosis Therapies Market Challenges
2.3.4 Multiple Sclerosis Therapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Multiple Sclerosis Therapies Players by Revenue
3.1.1 Global Top Multiple Sclerosis Therapies Players by Revenue (2020-2025)
3.1.2 Global Multiple Sclerosis Therapies Revenue Market Share by Players (2020-2025)
3.2 Global Multiple Sclerosis Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Multiple Sclerosis Therapies Revenue
3.4 Global Multiple Sclerosis Therapies Market Concentration Ratio
3.4.1 Global Multiple Sclerosis Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Multiple Sclerosis Therapies Revenue in 2024
3.5 Global Key Players of Multiple Sclerosis Therapies Head office and Area Served
3.6 Global Key Players of Multiple Sclerosis Therapies, Product and Application
3.7 Global Key Players of Multiple Sclerosis Therapies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Multiple Sclerosis Therapies Breakdown Data by Type
4.1 Global Multiple Sclerosis Therapies Historic Market Size by Type (2020-2025)
4.2 Global Multiple Sclerosis Therapies Forecasted Market Size by Type (2026-2031)
5 Multiple Sclerosis Therapies Breakdown Data by Application
5.1 Global Multiple Sclerosis Therapies Historic Market Size by Application (2020-2025)
5.2 Global Multiple Sclerosis Therapies Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Multiple Sclerosis Therapies Market Size (2020-2031)
6.2 North America Multiple Sclerosis Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Multiple Sclerosis Therapies Market Size by Country (2020-2025)
6.4 North America Multiple Sclerosis Therapies Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Multiple Sclerosis Therapies Market Size (2020-2031)
7.2 Europe Multiple Sclerosis Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Multiple Sclerosis Therapies Market Size by Country (2020-2025)
7.4 Europe Multiple Sclerosis Therapies Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Multiple Sclerosis Therapies Market Size (2020-2031)
8.2 Asia-Pacific Multiple Sclerosis Therapies Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Multiple Sclerosis Therapies Market Size by Region (2020-2025)
8.4 Asia-Pacific Multiple Sclerosis Therapies Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Multiple Sclerosis Therapies Market Size (2020-2031)
9.2 Latin America Multiple Sclerosis Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Multiple Sclerosis Therapies Market Size by Country (2020-2025)
9.4 Latin America Multiple Sclerosis Therapies Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Multiple Sclerosis Therapies Market Size (2020-2031)
10.2 Middle East & Africa Multiple Sclerosis Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Multiple Sclerosis Therapies Market Size by Country (2020-2025)
10.4 Middle East & Africa Multiple Sclerosis Therapies Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Multiple Sclerosis Therapies Introduction
11.1.4 Bayer Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.1.5 Bayer Recent Development
11.2 Biogen
11.2.1 Biogen Company Details
11.2.2 Biogen Business Overview
11.2.3 Biogen Multiple Sclerosis Therapies Introduction
11.2.4 Biogen Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.2.5 Biogen Recent Development
11.3 Bristol Myers Squibb
11.3.1 Bristol Myers Squibb Company Details
11.3.2 Bristol Myers Squibb Business Overview
11.3.3 Bristol Myers Squibb Multiple Sclerosis Therapies Introduction
11.3.4 Bristol Myers Squibb Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.3.5 Bristol Myers Squibb Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Multiple Sclerosis Therapies Introduction
11.4.4 Roche Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.4.5 Roche Recent Development
11.5 GSK
11.5.1 GSK Company Details
11.5.2 GSK Business Overview
11.5.3 GSK Multiple Sclerosis Therapies Introduction
11.5.4 GSK Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.5.5 GSK Recent Development
11.6 Merck Group
11.6.1 Merck Group Company Details
11.6.2 Merck Group Business Overview
11.6.3 Merck Group Multiple Sclerosis Therapies Introduction
11.6.4 Merck Group Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.6.5 Merck Group Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Multiple Sclerosis Therapies Introduction
11.7.4 Novartis Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 Teva Pharmaceutical Industries
11.8.1 Teva Pharmaceutical Industries Company Details
11.8.2 Teva Pharmaceutical Industries Business Overview
11.8.3 Teva Pharmaceutical Industries Multiple Sclerosis Therapies Introduction
11.8.4 Teva Pharmaceutical Industries Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.8.5 Teva Pharmaceutical Industries Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Multiple Sclerosis Therapies Introduction
11.9.4 Sanofi Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.9.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Multiple Sclerosis Therapies Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Acute Attack Treatment
 Table 3. Key Players of Disease Remission Treatment
 Table 4. Global Multiple Sclerosis Therapies Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Multiple Sclerosis Therapies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Multiple Sclerosis Therapies Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Multiple Sclerosis Therapies Market Share by Region (2020-2025)
 Table 8. Global Multiple Sclerosis Therapies Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Multiple Sclerosis Therapies Market Share by Region (2026-2031)
 Table 10. Multiple Sclerosis Therapies Market Trends
 Table 11. Multiple Sclerosis Therapies Market Drivers
 Table 12. Multiple Sclerosis Therapies Market Challenges
 Table 13. Multiple Sclerosis Therapies Market Restraints
 Table 14. Global Multiple Sclerosis Therapies Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Multiple Sclerosis Therapies Market Share by Players (2020-2025)
 Table 16. Global Top Multiple Sclerosis Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis Therapies as of 2024)
 Table 17. Ranking of Global Top Multiple Sclerosis Therapies Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Multiple Sclerosis Therapies Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Multiple Sclerosis Therapies, Headquarters and Area Served
 Table 20. Global Key Players of Multiple Sclerosis Therapies, Product and Application
 Table 21. Global Key Players of Multiple Sclerosis Therapies, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Multiple Sclerosis Therapies Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Multiple Sclerosis Therapies Revenue Market Share by Type (2020-2025)
 Table 25. Global Multiple Sclerosis Therapies Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Multiple Sclerosis Therapies Revenue Market Share by Type (2026-2031)
 Table 27. Global Multiple Sclerosis Therapies Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Multiple Sclerosis Therapies Revenue Market Share by Application (2020-2025)
 Table 29. Global Multiple Sclerosis Therapies Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Multiple Sclerosis Therapies Revenue Market Share by Application (2026-2031)
 Table 31. North America Multiple Sclerosis Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Multiple Sclerosis Therapies Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Multiple Sclerosis Therapies Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Multiple Sclerosis Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Multiple Sclerosis Therapies Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Multiple Sclerosis Therapies Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Multiple Sclerosis Therapies Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Multiple Sclerosis Therapies Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Multiple Sclerosis Therapies Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Multiple Sclerosis Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Multiple Sclerosis Therapies Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Multiple Sclerosis Therapies Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Multiple Sclerosis Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Multiple Sclerosis Therapies Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Multiple Sclerosis Therapies Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Bayer Company Details
 Table 47. Bayer Business Overview
 Table 48. Bayer Multiple Sclerosis Therapies Product
 Table 49. Bayer Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
 Table 50. Bayer Recent Development
 Table 51. Biogen Company Details
 Table 52. Biogen Business Overview
 Table 53. Biogen Multiple Sclerosis Therapies Product
 Table 54. Biogen Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
 Table 55. Biogen Recent Development
 Table 56. Bristol Myers Squibb Company Details
 Table 57. Bristol Myers Squibb Business Overview
 Table 58. Bristol Myers Squibb Multiple Sclerosis Therapies Product
 Table 59. Bristol Myers Squibb Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
 Table 60. Bristol Myers Squibb Recent Development
 Table 61. Roche Company Details
 Table 62. Roche Business Overview
 Table 63. Roche Multiple Sclerosis Therapies Product
 Table 64. Roche Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
 Table 65. Roche Recent Development
 Table 66. GSK Company Details
 Table 67. GSK Business Overview
 Table 68. GSK Multiple Sclerosis Therapies Product
 Table 69. GSK Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
 Table 70. GSK Recent Development
 Table 71. Merck Group Company Details
 Table 72. Merck Group Business Overview
 Table 73. Merck Group Multiple Sclerosis Therapies Product
 Table 74. Merck Group Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
 Table 75. Merck Group Recent Development
 Table 76. Novartis Company Details
 Table 77. Novartis Business Overview
 Table 78. Novartis Multiple Sclerosis Therapies Product
 Table 79. Novartis Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
 Table 80. Novartis Recent Development
 Table 81. Teva Pharmaceutical Industries Company Details
 Table 82. Teva Pharmaceutical Industries Business Overview
 Table 83. Teva Pharmaceutical Industries Multiple Sclerosis Therapies Product
 Table 84. Teva Pharmaceutical Industries Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
 Table 85. Teva Pharmaceutical Industries Recent Development
 Table 86. Sanofi Company Details
 Table 87. Sanofi Business Overview
 Table 88. Sanofi Multiple Sclerosis Therapies Product
 Table 89. Sanofi Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
 Table 90. Sanofi Recent Development
 Table 91. Research Programs/Design for This Report
 Table 92. Key Data Information from Secondary Sources
 Table 93. Key Data Information from Primary Sources
 Table 94. Authors List of This Report


List of Figures
 Figure 1. Multiple Sclerosis Therapies Picture
 Figure 2. Global Multiple Sclerosis Therapies Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Multiple Sclerosis Therapies Market Share by Type: 2024 VS 2031
 Figure 4. Acute Attack Treatment Features
 Figure 5. Disease Remission Treatment Features
 Figure 6. Global Multiple Sclerosis Therapies Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Multiple Sclerosis Therapies Market Share by Application: 2024 VS 2031
 Figure 8. Hospital Case Studies
 Figure 9. Clinic Case Studies
 Figure 10. Others Case Studies
 Figure 11. Multiple Sclerosis Therapies Report Years Considered
 Figure 12. Global Multiple Sclerosis Therapies Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 13. Global Multiple Sclerosis Therapies Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Multiple Sclerosis Therapies Market Share by Region: 2024 VS 2031
 Figure 15. Global Multiple Sclerosis Therapies Market Share by Players in 2024
 Figure 16. Global Top Multiple Sclerosis Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis Therapies as of 2024)
 Figure 17. The Top 10 and 5 Players Market Share by Multiple Sclerosis Therapies Revenue in 2024
 Figure 18. North America Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 19. North America Multiple Sclerosis Therapies Market Share by Country (2020-2031)
 Figure 20. United States Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Multiple Sclerosis Therapies Market Share by Country (2020-2031)
 Figure 24. Germany Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. France Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. U.K. Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Italy Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Russia Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Nordic Countries Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Multiple Sclerosis Therapies Market Share by Region (2020-2031)
 Figure 32. China Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Japan Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. South Korea Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Southeast Asia Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. India Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Australia Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Multiple Sclerosis Therapies Market Share by Country (2020-2031)
 Figure 40. Mexico Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Brazil Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Multiple Sclerosis Therapies Market Share by Country (2020-2031)
 Figure 44. Turkey Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Saudi Arabia Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. UAE Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Bayer Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
 Figure 48. Biogen Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
 Figure 49. Bristol Myers Squibb Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
 Figure 50. Roche Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
 Figure 51. GSK Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
 Figure 52. Merck Group Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
 Figure 53. Novartis Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
 Figure 54. Teva Pharmaceutical Industries Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
 Figure 55. Sanofi Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
 Figure 56. Bottom-up and Top-down Approaches for This Report
 Figure 57. Data Triangulation
 Figure 58. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure

SIMILAR REPORTS